Skip to main content
EVAX
NASDAQ Life Sciences

Evaxion to Present Three-Year EVX-01 Data at ESMO 2026; Two-Year Results Show 75% ORR

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.12
Mkt Cap
$26.021M
52W Low
$2.45
52W High
$12.15
52W Position info
27% above low
Off High info
74% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

EVAX sits 27% above its 52-week low of $2.45.

Summary

Evaxion announced it will present three-year efficacy data for its personalized cancer vaccine EVX-01 at ESMO 2026. The two-year data showed a 75% response rate and durable responses in advanced melanoma.


Key Events · Product Development and Regulatory · EVAX

  • ESMO 2026 Presentation

    Three-year clinical efficacy data for personalized cancer vaccine EVX-01 will be presented at the ESMO Congress on October 24, 2026.

  • Two-Year Efficacy Data

    Previously reported two-year data showed a 75% objective response rate (12/16 patients), 92% durable response rate, and 54% deepened response rate in advanced melanoma.

  • Stand-Alone Therapy Data

    Third-year data will include results from patients receiving EVX-01 as stand-alone therapy, potentially demonstrating vaccine effect without anti-PD-1 combination.

  • Partnership Catalyst

    Presentation at a major oncology conference provides an opportunity to discuss data with potential business partners amid emerging pivotal data in the personalized cancer vaccine field.


Analysis · EVAX · Life Sciences

A major oncology conference sets the stage for Evaxion to unveil three-year clinical efficacy data from its lead personalized cancer vaccine, EVX-01, at the ESMO Congress in October 2026. The two-year snapshot already delivered a 75% objective response rate and durable responses in advanced melanoma. With the upcoming readout including stand-alone therapy results, the case for EVX-01 as a differentiated asset could strengthen considerably. For a company with a $26M market cap, positive data at this venue can serve as a powerful catalyst for partnership discussions and investor sentiment.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVAX was trading at $3.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26M. The 52-week trading range was $2.45 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVAX - Latest Insights

EVAX
Oct 23, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.78 info
Change: -$1.26 (-31%) info
Market Cap: $23.102M info
EVAX
Oct 19, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.78 info
Change: -$0.474 (-15%) info
Market Cap: $23.102M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $2.78 info
Change: -$0.694 (-20%) info
Market Cap: $23.102M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $2.78 info
Change: -$0.699 (-20%) info
Market Cap: $23.102M info
EVAX
Aug 17, 2026, 8:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.34
Real-time Price: $2.78 info
Change: -$0.564 (-17%) info
Market Cap: $23.102M info